IGC Pharma, Inc. financial data

Symbol
IGC on NYSE
Location
10224 Falls Road, Potomac, MD
Fiscal year end
March 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 131 % -34.9%
Quick Ratio 59.9 % -30.2%
Debt-to-equity 38.8 % +50%
Return On Assets -70.2 % +36.3%
Operating Margin -524 % +44.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 83.9M shares +10.9%
Common Stock, Shares, Outstanding 84.1M shares +11.2%
Entity Public Float 29.7M USD +42.3%
Weighted Average Number of Shares Outstanding, Basic 83M shares +14%
Weighted Average Number of Shares Outstanding, Diluted 83M shares +14%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.33M USD +25%
Cost of Revenue 717K USD +70.3%
Research and Development Expense 3.62M USD -7.61%
Operating Income (Loss) -6.96M USD +30.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.34M USD +52.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6.34M USD +52.3%
Earnings Per Share, Basic 0 USD/shares +33.3%
Earnings Per Share, Diluted 0 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 454K USD -75.1%
Marketable Securities, Current 154K USD
Accounts Receivable, after Allowance for Credit Loss, Current 87K USD +211%
Inventory, Net 1.35M USD -10.7%
Other Assets, Current 148K USD -38.3%
Assets, Current 2.15M USD -51.1%
Property, Plant and Equipment, Net 3.1M USD -13.6%
Operating Lease, Right-of-Use Asset 16K USD -91.7%
Intangible Assets, Net (Excluding Goodwill) 2M USD +16.1%
Other Assets, Noncurrent 680K USD -1.16%
Assets 7.94M USD -25%
Accounts Payable, Current 933K USD +21%
Employee-related Liabilities, Current 191K USD -81.1%
Accrued Liabilities, Current 792K USD -53.9%
Liabilities, Current 1.73M USD -30.7%
Operating Lease, Liability, Noncurrent 7K USD -89.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 1.87M USD -31.3%
Common Stocks, Including Additional Paid in Capital 132M USD +3.59%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.5M USD -2.13%
Retained Earnings (Accumulated Deficit) -122M USD -5.43%
Stockholders' Equity Attributable to Parent 6.08M USD -22.9%
Liabilities and Equity 7.94M USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.41M USD +19.7%
Net Cash Provided by (Used in) Financing Activities 851K USD -66.1%
Net Cash Provided by (Used in) Investing Activities 580K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 84.1M shares +11.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 49K USD -92.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 454K USD -75.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD 0%
Deferred Tax Assets, Valuation Allowance 19.1M USD +27.7%
Deferred Tax Assets, Gross 19.1M USD +27.7%
Operating Lease, Liability 103K USD -50.5%
Depreciation 552K USD -2.82%
Payments to Acquire Property, Plant, and Equipment 8K USD -78.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.37M USD +52.3%
Lessee, Operating Lease, Liability, to be Paid 340K USD -26.7%
Property, Plant and Equipment, Gross 5.92M USD -3.97%
Operating Lease, Liability, Current 62K USD -53.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10K USD -88.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 96K USD -27.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -72.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 14K USD -30%
Depreciation, Depletion and Amortization 141K USD -13%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 452K USD +12.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%